Janux Therapeutics, Inc.JANXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+259.0%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+259.0%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
46.3x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 517.65% |
| Q3 2025 | 46.01% |
| Q2 2025 | -39.88% |
| Q1 2025 | -1.79% |
| Q4 2024 | -649.66% |
| Q3 2024 | 77.74% |
| Q2 2024 | 32.46% |
| Q1 2024 | -49.85% |
| Q4 2023 | 15.44% |
| Q3 2023 | 22.22% |
| Q2 2023 | -8.22% |
| Q1 2023 | -16.77% |
| Q4 2022 | 11.19% |
| Q3 2022 | -120.88% |
| Q2 2022 | 47.29% |
| Q1 2022 | -9.93% |
| Q4 2021 | -79.04% |
| Q3 2021 | 5.64% |
| Q2 2021 | -211.52% |
| Q1 2021 | 441.50% |
| Q4 2020 | -50.42% |
| Q3 2020 | -38.67% |
| Q2 2020 | 10.84% |
| Q1 2020 | 0.00% |